6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Paracellular permeability and tight junction regulation in gut health and disease

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Epithelial tight junctions define the paracellular permeability of the intestinal barrier. Molecules can cross the tight junctions via two distinct size-selective and charge-selective paracellular pathways: the pore pathway and the leak pathway. These can be distinguished by their selectivities and differential regulation by immune cells. However, permeability increases measured in most studies are secondary to epithelial damage, which allows non-selective flux via the unrestricted pathway. Restoration of increased unrestricted pathway permeability requires mucosal healing. By contrast, tight junction barrier loss can be reversed by targeted interventions. Specific approaches are needed to restore pore pathway or leak pathway permeability increases. Recent studies have used preclinical disease models to demonstrate the potential of pore pathway or leak pathway barrier restoration in disease. In this Review, we focus on the two paracellular flux pathways that are dependent on the tight junction. We discuss the latest evidence that highlights tight junction components, structures and regulatory mechanisms, their impact on gut health and disease, and opportunities for therapeutic intervention.

          Abstract

          Increased intestinal permeability owing to tight junction barrier loss could be targeted in gastrointestinal diseases associated with increased permeability. In this Review, the authors discuss the molecular components and regulation of the tight junction, and consider the relevance to gut diseases and therapeutic opportunities.

          Key points

          • Increased intestinal permeability occurs in a wide range of disorders, including inflammatory bowel disease, coeliac disease and graft-versus-host disease, but the relative contributions of barrier dysfunction and immune responses are unclear.

          • Intestinal barrier loss can be a consequence of tight junction dysfunction or of epithelial damage; in most studies, these mechanisms are not distinguished.

          • Paracellular transport across the tight junction can occur via the pore pathway or the leak pathway, which have distinct size-selectivity and charge-selectivity and are differentially regulated by immune signalling.

          • Claudin-2 increases Na + and water flux across the pore pathway but larger molecules are unable to traverse claudin-2 channels.

          • The leak pathway allows macromolecules to cross the epithelial barrier and is regulated by the cytoskeleton and epithelial long myosin light chain kinase splice variant 1 (MLCK1).

          • Blocking MLCK1 recruitment to the tight junction limits tight junction barrier loss without interfering with essential MLCK functions in epithelial cells and cells of other types.

          Related collections

          Most cited references294

          • Record: found
          • Abstract: found
          • Article: found

          SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

          Summary There is pressing urgency to understand the pathogenesis of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2), which causes the disease COVID-19. SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry. The cell subsets targeted by SARS-CoV-2 in host tissues and the factors that regulate ACE2 expression remain unknown. Here, we leverage human, non-human primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and disease to uncover putative targets of SARS-CoV-2 among tissue-resident cell subsets. We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. Strikingly, we discovered that ACE2 is a human interferon-stimulated gene (ISG) in vitro using airway epithelial cells and extend our findings to in vivo viral infections. Our data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Interactions between the microbiota and the immune system.

            The large numbers of microorganisms that inhabit mammalian body surfaces have a highly coevolved relationship with the immune system. Although many of these microbes carry out functions that are critical for host physiology, they nevertheless pose the threat of breach with ensuing pathologies. The mammalian immune system plays an essential role in maintaining homeostasis with resident microbial communities, thus ensuring that the mutualistic nature of the host-microbial relationship is maintained. At the same time, resident bacteria profoundly shape mammalian immunity. Here, we review advances in our understanding of the interactions between resident microbes and the immune system and the implications of these findings for human health.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

              Objective The SARS-CoV-2-infected disease (COVID-19) outbreak is a major threat to human beings. Previous studies mainly focused on Wuhan and typical symptoms. We analysed 74 confirmed COVID-19 cases with GI symptoms in the Zhejiang province to determine epidemiological, clinical and virological characteristics. Design COVID-19 hospital patients were admitted in the Zhejiang province from 17 January 2020 to 8 February 2020. Epidemiological, demographic, clinical, laboratory, management and outcome data of patients with GI symptoms were analysed using multivariate analysis for risk of severe/critical type. Bioinformatics were used to analyse features of SARS-CoV-2 from Zhejiang province. Results Among enrolled 651 patients, 74 (11.4%) presented with at least one GI symptom (nausea, vomiting or diarrhoea), average age of 46.14 years, 4-day incubation period and 10.8% had pre-existing liver disease. Of patients with COVID-19 with GI symptoms, 17 (22.97%) and 23 (31.08%) had severe/critical types and family clustering, respectively, significantly higher than those without GI symptoms, 47 (8.14%) and 118 (20.45%). Of patients with COVID-19 with GI symptoms, 29 (39.19%), 23 (31.08%), 8 (10.81%) and 16 (21.62%) had significantly higher rates of fever >38.5°C, fatigue, shortness of breath and headache, respectively. Low-dose glucocorticoids and antibiotics were administered to 14.86% and 41.89% of patients, respectively. Sputum production and increased lactate dehydrogenase/glucose levels were risk factors for severe/critical type. Bioinformatics showed sequence mutation of SARS-CoV-2 with m6A methylation and changed binding capacity with ACE2. Conclusion We report COVID-19 cases with GI symptoms with novel features outside Wuhan. Attention to patients with COVID-19 with non-classic symptoms should increase to protect health providers.
                Bookmark

                Author and article information

                Contributors
                jrturner@bwh.harvard.edu
                Journal
                Nat Rev Gastroenterol Hepatol
                Nat Rev Gastroenterol Hepatol
                Nature Reviews. Gastroenterology & Hepatology
                Nature Publishing Group UK (London )
                1759-5045
                1759-5053
                25 April 2023
                : 1-16
                Affiliations
                [1 ]GRID grid.460771.3, ISNI 0000 0004 1785 9671, UNIROUEN, INSERM U1245, Normandy Centre for Genomic and Personalized Medicine, , Normandie University, ; Rouen, France
                [2 ]GRID grid.62560.37, ISNI 0000 0004 0378 8294, Laboratory of Mucosal Barrier Pathobiology, Department of Pathology, , Brigham and Women’s Hospital, Harvard Medical School, ; Boston, MA USA
                Author information
                http://orcid.org/0000-0001-6239-1287
                http://orcid.org/0000-0002-5889-8576
                http://orcid.org/0000-0003-1186-9986
                http://orcid.org/0000-0003-0627-9455
                Article
                766
                10.1038/s41575-023-00766-3
                10127193
                37186118
                446a0392-f973-47aa-ab66-d5e92d8cbc3f
                © Springer Nature Limited 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 3 March 2023
                Categories
                Review Article

                gastroenterology,gastrointestinal system,inflammatory bowel disease

                Comments

                Comment on this article